MAPT and Alzheimer disease: Recent advances in brain imaging and more sensitive and specific means to detect Aβ and tau in biological fluids, associated with our ability to detect loss of brain matter, metabolism or function, have allowed for development of a classification and staging system for AD, the ATN system [80], which is routinely revised [81], to include the everchanging horizon of new biomarkers available.